Regencell Bioscience Holdings Limited (NASDAQ:RGC) Sees Significant Growth in Short Interest

Regencell Bioscience Holdings Limited (NASDAQ:RGC) was the target of a large growth in short interest in April. As of April 15th, there was short interest totaling 830,632 shares, a growth of 18.6% from the March 31st total of 700,509 shares. Based on an average daily trading volume, of 242,253 shares, the short-interest ratio is presently 3.4 days. Currently, 0.2% of the company’s stock are sold short.

Hedge Funds Weigh In On Regencell Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new position in shares of Regencell Bioscience in the 4th quarter valued at approximately $92,000. Vident Advisory LLC raised its position in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Regencell Bioscience in the 4th quarter valued at approximately $275,000. XTX Topco Ltd purchased a new position in shares of Regencell Bioscience in the 3rd quarter valued at approximately $598,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Regencell Bioscience in the 2nd quarter valued at approximately $768,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Stock Down 0.3%

Shares of NASDAQ:RGC traded down $0.10 during trading on Friday, reaching $29.12. The stock had a trading volume of 60,148 shares, compared to its average volume of 344,060. Regencell Bioscience has a one year low of $1.53 and a one year high of $83.60. The firm’s 50-day simple moving average is $27.10 and its 200 day simple moving average is $23.54.

More Regencell Bioscience News

Here are the key news stories impacting Regencell Bioscience this week:

• Negative Sentiment: Faruqi & Faruqi reminds Regencell (RGC) investors of the June 23, 2026 deadline to seek lead‑plaintiff status and says it is investigating claims on behalf of purchasers during the alleged class period. Faruqi & Faruqi notice
• Negative Sentiment: The Gross Law Firm notifies RGC shareholders of a potential class action and invites affected investors to contact the firm about lead‑plaintiff appointment. Gross Law Firm notice
• Negative Sentiment: Pomerantz LLP filed a class action in U.S. District Court for the District of Maryland seeking damages under Sections 10(b) and 20(a) related to the same Oct. 28, 2024–Oct. 31, 2025 period. Pomerantz filing
• Negative Sentiment: Multiple other firms (Kaplan Fox, Rosen, Bronstein Gewirtz, Portnoy Law, Glancy Prongay, Frank R. Cruz and others) have issued alerts or launched investigations urging shareholders to act before the June 23 deadline, expanding the litigation spotlight on the company. Kaplan Fox alert (example)
• Negative Sentiment: Business press items and wire notices amplify investor awareness of the lawsuits and investigations, increasing short‑term volatility and downside pressure until legal exposure is clarified. Business Wire investigation notice

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.